REDWOOD CITY, Calif., Sept. 2, 2026

Revolution Medicines, Inc. (Nasdaq: RVMD), a commercial-stage oncology company focused on RAS-driven cancers, announced that The New England Journal of Medicine (NEJM) has published clinical data from the Phase 1/2 study of RASONQUE™ (daraxonrasib) in patients with previously treated RAS-mutant non-small cell lung cancer (NSCLC). The publication represents an important clinical-development milestone for RASONQUE as Revolution Medicines continues advancing the therapy through its global RASolve 301 Phase 3 trial. RASONQUE is an oral RAS(ON) multi-selective inhibitor designed to target the active state of RAS, one of the key cancer-driving signaling pathways in multiple tumor types. The company said the published findings further support the clinical rationale for evaluating RASONQUE in a broader population of patients with RAS-mutant metastatic NSCLC.

NEJM Publication Strengthens Clinical Rationale for RASolve 301

The NEJM publication is based on data from the Phase 1/2 RMC-6236-001 study, which evaluated RASONQUE in patients with advanced RAS-mutant NSCLC whose disease had progressed following, or who were intolerant to, platinum-based chemotherapy and anti-PD-(L)1 therapy. The study included patients with a range of RAS mutations other than RAS G12C, an important distinction because targeted treatment options remain limited for many patients with other RAS alterations. According to Revolution Medicines, the study demonstrated dose-dependent antitumor activity alongside a manageable safety profile. In a subgroup of 38 docetaxel-naïve patients treated at 160 mg to 220 mg, RASONQUE produced a 42% confirmed objective response rate and an 89% disease control rate. These findings provided the clinical foundation for the company’s ongoing pivotal development program.

RASONQUE Moves Forward in Global Phase 3 NSCLC Study

The Phase 1/2 findings have informed the design of RASolve 301, an ongoing global, randomized, open-label Phase 3 clinical trial comparing RASONQUE with docetaxel in patients with previously treated, locally advanced or metastatic RAS-mutant NSCLC. The study represents the next major development step for RASONQUE in lung cancer and is intended to determine whether the treatment can provide a clinically meaningful benefit compared with an established chemotherapy option. Revolution Medicines is developing RASONQUE to address a broad range of RAS-driven cancers, rather than limiting its approach to a single RAS mutation. The company believes the NEJM publication adds further independent visibility to the clinical evidence supporting this development strategy.

Advertisement

cGxPJobs Banner

Revolution Medicines Expands RAS(ON) Strategy Across RAS-Driven Cancers

Revolution Medicines is advancing RASONQUE through a broader clinical strategy focused on directly targeting RAS(ON), the active cancer-driving state of RAS proteins. RASONQUE has already received U.S. FDA approval for previously treated metastatic pancreatic adenocarcinoma, while its use in RAS-mutant NSCLC remains investigational. The company is also advancing a global Phase 3 program across pancreatic cancer and NSCLC, with the long-term objective of expanding targeted treatment options for patients whose tumors are driven by different RAS alterations. The publication of the Phase 1/2 NSCLC data in The New England Journal of Medicine therefore represents a significant scientific and clinical milestone as Revolution Medicines continues to evaluate the potential of its RAS(ON) inhibitor platform in major RAS-driven cancers.

Source:Revolution Medicines,, press relese